A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Study Details
Study Description
Brief Summary
This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part, a biopsy part (the part to evaluate biomarkers), and an expansion part.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Part A: Dose-escalation part of Phase Ia Patients will receive ROSE12 as a IV infusion at escalated doses. |
Drug: ROSE12
ROSE12 as a IV infusion
|
| Experimental: Part B: Biopsy part of Phase Ia Serial biopsy will be conducted with patients who will receive ROSE12 as a IV infusion at escalated doses. |
Drug: ROSE12
ROSE12 as a IV infusion
|
| Experimental: Part C: Dose-escalation part of Phase Ib Patients will receive ROSE12 and atezolizumab as a IV infusion at escalated doses. |
Drug: ROSE12
ROSE12 as a IV infusion
Drug: Atezolizumab
Atezolizumab as a IV infusion
|
| Experimental: Part D: Biopsy part of Phase Ib Serial biopsy will be conducted with patients who will receive ROSE12 and atezolizumab as a IV infusion at escalated doses. |
Drug: ROSE12
ROSE12 as a IV infusion
Drug: Atezolizumab
Atezolizumab as a IV infusion
|
| Experimental: Part E: Expansion part of Phase Ib in patients with selected solid tumors Patients will receive ROSE12 and atezolizumab as a IV infusion at the recommended dose. |
Drug: ROSE12
ROSE12 as a IV infusion
Drug: Atezolizumab
Atezolizumab as a IV infusion
|
Outcome Measures
Primary Outcome Measures
- The maximum tolerated dose (MTD) and the recommended dose (RD) of ROSE12 when administered as a single agent and in combination with atezolizumab (Part A and C) [From Cycle 1 Day 1 until Cycle 1 Day 21 (Cycle 1 is 21 days)]
Incidence and nature of dose-limiting toxicities (DLTs)
- Safety (All Parts) and tolerability (Part A, B, C and D) of ROSE12 when administered as a single agent and in combination with atezolizumab (Adverse Events) [From screening until study completion, treatment discontinuation or post-treatment follow up, assessed up to the end of the study (approximate 43 months)]
Incidence, nature, and severity of adverse events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
- The maximum serum concentration (Cmax) of ROSE12 for PK profile when administered as a single agent and in combination with atezolizumab (All Parts) [From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)]
The maximum serum concentration (Cmax) of ROSE12
- The minimum serum concentration (Cmin) of ROSE12 for PK profile when administered as a single agent and in combination with atezolizumab (All Parts) [From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)]
The minimum serum concentration (Cmin) of ROSE12
- The area under the concentration time-curve (AUC) of ROSE12 for PK profile when administered as a single agent and in combination with atezolizumab (All Parts) [From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)]
The area under the concentration time-curve (AUC) of ROSE12
- Preliminary anti-tumor activity of ROSE12 when administered in combination with atezolizumab (Part E) [From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)]
Objective response rate (ORR), defined as the proportion of patients with an objective response (complete response [CR] or partial response [PR]) on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to the Response Evaluation Criteria in Solid Tumors version 1.1
Secondary Outcome Measures
- Preliminary anti-tumor activity of ROSE12 when administered as a single agent and in combination with atezolizumab (Part A, B, C and D) [From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)]
ORR, defined as the proportion of patients with an objective response on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to RECIST v1.1.
- Preliminary anti-tumor activity of ROSE12 when administered as a single agent and in combination with atezolizumab (All Parts) [From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)]
Disease control rate (DCR), defined as the proportion of patients who had an objective response or stable disease (SD) which is confirmed no less than 6 weeks after the start of treatment as the minimum duration, as determined by the investigator with use of RECIST v1.1.
- Preliminary anti-tumor activity of ROSE12 when administered as a single agent and in combination with atezolizumab (All Parts) [From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)]
Duration of objective response (DoR), defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1.
- Preliminary anti-tumor activity of ROSE12 when administered as a single agent and in combination with atezolizumab (All Parts) [From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)]
Progression-free survival (PFS), defined as the time from administration of first study treatment to the first occurrence of disease progression or death from any cause, as determined by the investigator according to RECIST v1.1.
- The maximum serum concentration (Cmax) of atezolizumab for PK profile when administered in combination with ROSE12 (Part C, D and E) [From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)]
The maximum serum concentration (Cmax) of atezolizumab
- The minimum serum concentration (Cmin) of atezolizumab for PK profile when administered in combination with ROSE12 (Part C, D and E) [From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)]
The minimum serum concentration (Cmin) of atezolizumab
- The area under the concentration-time curve (AUC) of atezolizumab for PK profile when administered in combination with ROSE12 (Part C, D and E) [From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)]
The area under the concentration-time curve (AUC) of atezolizumab
- The immunogenicity of ROSE12 when administered as a single agent and in combination with atezolizumab (All Parts) [From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)]
Prevalence and incidence of anti-drug antibodies (ADAs) to ROSE12 and potential correlation with PK parameters and safety
- The immunogenicity of atezolizumab when administered in combination with ROSE12 (Part C, D and E) [From Cycle 1 Day 1 (Cycle 1 is 21 days) until study completion or treatment discontinuation, assessed up to the end of the study (approximate 43 months)]
Prevalence and incidence of ADAs to atezolizumab and potential correlation with PK parameters and safety
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 18 years at time of signing informed consent form (ICF)
-
Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1
-
Adequate hematologic and end-organ function
-
Life expectancy ≥ 12 weeks
-
Patients with histologic documentation of locally advanced, or metastatic solid tumor
-
[Dose-escalation Parts and Expansion Part] Patients with confirmed availability of fresh tumor or representative tumor specimens
-
[Biopsy Parts] Patients with accessible lesion(s)
Exclusion Criteria:
-
Clinically significant cardiovascular or liver disease
-
Treatment with investigational therapy and anti-cancer therapy within 28 days prior to initiation of study drug
-
Any history of an immune-mediated Grade 4 adverse event attributed to prior cancer immunotherapy (other than asymptomatic elevation of serum amylase or lipase).
-
All imAEs from prior cancer immunotherapy (other than endocrinopathy managed with replacement therapy, stable vitiligo or stable alopecia) that have not resolved completely to baseline.
-
Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1 except for alopecia, vitiligo, or endocrinopathy managed with replacement therapy
-
Primary central nervous system (CNS) malignancy, untreated CNS metastases requiring any anti-tumor treatment, or active CNS metastases
-
Uncontrolled tumor-related pain
-
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
-
Active or history of clinically significant autoimmune disease
-
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
[Expansion Part]
-
Prior treatment with investigational product which has MoA of Treg depletion
-
Malignancies other than disease under study within 5 years prior to Cycle 1 Day 1
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National Cancer Center Hospital | Chuo-ku | Tokyo | Japan | 1040045 |
Sponsors and Collaborators
- Chugai Pharmaceutical
Investigators
- Study Director: Sponsor Chugai Pharmaceutical Co.Ltd, clinical-trials@chugai-pharm.co.jp
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RSE101CT